Say It With Technology: How Alnylam Fosters A Connected Relationship With Sites

Alnylam Pharmaceuticals is developing an entirely new class of medicines and delivered the world’s first and only approved RNAi therapeutics in 2018 and 2019. Learn how Alnylam earned its reputation among investigators as a sponsor of choice by standardizing studies on a collaborative portal more than 6 years ago and leveraging technology to deliver:

• Informative, engaging, and inspirational communities for sites
• Digital study management that minimizes administrative burden
• Learning management that helps every site succeed, even first-time investigators
• Protocol-specific solutions that facilitate pre-screening scenarios, guide complicated visit scheduling, and protect patients

Speakers

• James (Jimmy) Keegan, Clinical Trial Specialist, Alnylam Pharmaceuticals
• Saraba Kuchibhotla, MPH, Clinical Trial Specialist, Alnylam Pharmaceuticals
• Tennyson Hunt, Clinical Trial Specialist, Alnylam Pharmaceuticals
• Lesley Freese, Assoc. Director, Trial Operations, IQVIA Technologies